Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.50 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.36 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.36 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.36 |
| ▸ | KHK | P50053 | 2/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1950482 | 1.00 | HPGD (0.59) | HPGDKMT2ASMN1; SMN2HTR6CHRNB2 | |
| SCHEMBL894571 | 0.97 | — | — | |
| SCHEMBL63548 | 0.97 | — | — | |
| Ammonia Solution, Strong SCHEMBL19410292 | 0.94 | HPGD (0.53) | HPGDKMT2ASMN1; SMN2HTR6CHRNB2 | |
| Hydrochloric Acid SCHEMBL31605521 | 0.92 | KMT2A (0.52) | HPGDKMT2ASMN1; SMN2HTR6CHRNB2 | |
| SCHEMBL2554458 | 0.92 | HPGD (0.52) | HPGDKMT2ASMN1; SMN2HTR6CHRNB2 | |
| Hydrochloric Acid SCHEMBL2973444 | 0.90 | HTR6 (0.54) | HPGDKMT2ASMN1; SMN2HTR6L3MBTL3 | |
| Hydrochloric Acid SCHEMBL452359 | 0.89 | HTR6 (0.64) | HPGDKMT2ASMN1; SMN2HTR6L3MBTL3 | |
| Hydrochloric Acid SCHEMBL452523 | 0.89 | HTR6 (0.58) | HPGDKMT2ASMN1; SMN2HTR6CHRNB2 | |
| Hydrochloric Acid SCHEMBL450071 | 0.89 | HTR6 (0.58) | HPGDKMT2ASMN1; SMN2HTR6CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534463-B2 | Substituted tricyclic compounds as FGFR inhibitors | INCYTE CORPORATION (US) | 2026-01-27 | — | — | US | disclosed |
| CN-119462566-A | Preparation method of 1-cyclopropyl piperazine | 安徽皓元药业有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20240246974-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | INCYTE CORPORATION | 2024-07-25 | — | — | US | disclosed |
| EP-4403216-A2 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | Incyte Holdings Corporation (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-3822273-B1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | INCYTE HOLDINGS CORP (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240043395-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. | 2024-02-08 | — | — | US | disclosed |
| US-11840534-B2 | Substituted tricyclic compounds as FGFR inhibitors | INCYTE CORPORATION (US) | 2023-12-12 | — | — | US | disclosed |
| EP-4217342-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | Neuropore Therapies, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116507607-A | Compounds and compositions as modulators of TLR signaling | 神经孔疗法股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2022067114-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| EP-0729469-A1 | IMIDAZO [1,5-a]QUINOLINES FOR TREATMENT OF ANXIETY AND SLEEP DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 1996-09-04 | — | — | EP | disclosed |
| EP-0679645-A1 | Pharmacologically active CNS pyridmidin compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-11-02 | — | — | EP | disclosed |
| WO-1995024207-A1 | COMPOSITION FOR THE TREATMENT OF LUNG DISEASE | MERCK & CO., INC. (US) | 1995-09-14 | — | — | WO | disclosed |
| WO-1995014020-A1 | IMIDAZO[1,5-a]QUINOLINES FOR TREATMENT OF ANXIETY AND SLEEP DISORDERS | THE UPJOHN COMPANY (US) | 1995-05-26 | — | — | WO | disclosed |
| WO-1994010142-A1 | NEW SUBSTITUTED AZETIDINONES AS ANTI-INFLAMMATORY AND ANTIDEGENERATIVE AGENTS | MERCK & CO., INC. (US) | 1994-05-11 | — | — | WO | disclosed |
| EP-0595557-A1 | New substituted azetidinones as anti-inflammatory and antidegenerative agents | MERCK & CO. INC. (US) | 1994-05-04 | — | — | EP | disclosed |
| EP-0459819-A2 | Pharmacologically active CNS compound | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-12-04 | — | — | EP | disclosed |
| EP-0224178-B1 | 1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-4-OXO-7(1-PIPERAZINYL)-3-QUINOLINE-CARBOXYLIC ACIDS, PROCESS FOR THEIR PREPARATION AND ANTIBACTERIAL COMPOSITIONS CONTAINING THEM | BAYER AG (DE) | 1990-08-01 | — | — | EP | disclosed |
| US-4806539-A | 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acids and antibacterial agents containing them | BAYER AKTIENGESELLSCHAFT (DE) | 1989-02-21 | — | — | US | disclosed |
| EP-0224178-A1 | 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7(1-piperazinyl)-3-quinoline-carboxylic acids, process for their preparation and antibacterial compositions containing them | BAYER AG (DE) | 1987-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534463-B2 | Substituted tricyclic compounds as FGFR inhibitors | FGFR3, FGFR1, FGFR4 | HTR6 984/4885CHRNA3 2209/4885HRH3 3235/4885 |
| US-20240043395-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | TLR3, TLR6, TLR4 | HTR6 911/4885CHRNA3 2429/4885HRH3 2448/4885 |
| US-11840534-B2 | Substituted tricyclic compounds as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | HTR6 3474/4885CHRNA3 4840/4885HRH3 3673/4885 |
| US-20240246974-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | FGFR3, FGFR1, FGFR2 | HTR6 3474/4885CHRNA3 4840/4885HRH3 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.